Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54861911 proof-of-mechanism study in early Alzheimer's disease
NL-OMON40301Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of atabecestat in Alzheimer's disease (AD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change in CSF Aβ1-40 after 4 weeks, Change in plasma Aβ1-40 after 4 weeks and 3 more. Started Mar 2014; status: active, not recruiting.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON40301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40301.